Roivant Sciences Ltd.
ROIV | NASDAQ
$39.41
-$0.36 (-0.91%)
Sep 21, 2026, 11:07 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Mar 30, 2026 | FY 2024 Mar 30, 2025 | FY 2023 Mar 30, 2024 | FY 2022 Mar 30, 2023 | FY 2021 Mar 30, 2022 | FY 2020 Mar 30, 2021 |
|---|---|---|---|---|---|---|
Revenue | 8.26M | 29.05M | 32.71M | 31.53M | 55.29M | 23.8M |
Cost of Revenue | 1.29M | 911K | 1.6M | 3.03M | 8.97M | 2.06M |
Gross Profit | 6.98M | 28.14M | 31.11M | 28.5M | 46.32M | 21.74M |
Operating Income | -1.29B | -1.11B | -824.93M | -809.01M | -1.21B | -1.07B |
Interest Income | 178.11M | 258.38M | 146.43M | 32.18M | 369K | 1.42M |
Pretax Income | -264.58M | -681.59M | 4.57B | -884.99M | -923.75M | -898.55M |
Net Income | -299.77M | -171.98M | 4.35B | -1.01B | -845.26M | -809.23M |
Selling & General & Admin | 610.47M | 591.41M | 416.13M | 383.45M | 775.03M | 259.88M |
Research & Development | 681.81M | 550.41M | 439.91M | 454.06M | 483.04M | 236.63M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 596.13M |
Operating Expenses | 1.29B | 1.14B | 856.04M | 837.51M | 1.26B | 1.09B |
Interest Expense | n/a | n/a | 34.78M | 27.97M | 7.04M | 2.81M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.29B | 1.14B | 857.64M | 840.54M | 1.27B | 1.09B |
Income Tax Expense | 133.33M | 48.17M | 21.5M | 4.08M | 369K | 1.69M |
Shares Outstanding (Basic) | 693.86M | 725.4M | 783.25M | 712.79M | 669.75M | 684.79M |
Shares Outstanding (Diluted) | 693.86M | 725.4M | 831.05M | 712.79M | 669.75M | 684.79M |
EPS (Basic) | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | -1.18 |
EPS (Diluted) | -0.43 | -0.24 | 5.23 | -1.42 | -1.26 | -1.18 |
EBITDA | -261.23M | -667.52M | 4.62B | -838.17M | -910.77M | -895.74M |
EBIT | -264.58M | -681.59M | 4.6B | -857.02M | -916.71M | -895.74M |
Depreciation & Amortization | 3.35M | 14.07M | 22.04M | 18.86M | 5.93M | n/a |
Add to Watchlist
Select watchlists to add or remove ROIV